Cell Therapeutics, Inc. (CTI) Supports Panel Discussion On Women And Lung Cancer On Capitol Hill

Cell Therapeutics, Inc.
(CTI) (Nasdaq: CTIC; MTAX:), along with the Society for Women's Health
Research, the Lung Cancer Alliance and others, will support a panel
discussion entitled "Lung Cancer: Being Female Matters to Research," on
Capitol Hill to discuss advances in the research and treatment of lung
cancer in women on Monday, September 17.


CTI has been conducting clinical trials of its investigational drug,
XYOTAX(TM), researching how estrogen levels affect a woman's response to
treatment for lung cancer. Data collected from recent XYOTAX trials
suggests that estrogen levels may alter the effectiveness of cancer
treatment, and that women with higher levels of estrogen had a lower rate
of survival in cases of lung cancer.



The event will be held in room B-340 of the Rayburn House Office
Building from noon to 1:30 p.m. Speakers will include Laurie Fenton
Ambrose, President of the Lung Cancer Alliance, Joan H. Schiller, M.D.,
Chief of Hematology and Oncology at the University of Texas Southwestern
Medical Center and Deputy Director of Simmons Comprehensive Cancer Center,
and Jill M. Siegfried, Ph.D., Professor and Vice Chair of Pharmacology at
the University of Pittsburgh School of Medicine and co-Director of the Lung
and Esophageal Cancer Program at the University of Pittsburgh Cancer
Institute (UPCI).



Women and Lung Cancer



Lung cancer is the number one cancer killer of women in the United
States -- more than breast and ovarian cancers combined. The American
Cancer Society estimates that in 2007 there will be approximately 213,490
new cases of lung cancer in the United States -- up 22 percent from 2006.
Of those new cases, 98,620 will be among women -- up 20 percent from a year
ago. One in 16 women will develop lung cancer in their lifetime.



"Gender does matter -- especially when it comes to lung cancer," said
James A. Bianco, M.D., president and CEO of CTI. "This should be a national
wake up call for increased awareness and research into lung cancer and
gender-based medicine. Women are affected by lung cancer differently than
men, and they respond differently to treatment. Through our XYOTAX studies,
we continue to explore ways to turn a negative -- high levels of estrogen
-- into a positive in our continuing efforts to make cancer more
treatable."



About XYOTAX(TM)



XYOTAX(TM) (paclitaxel poliglumex) is a biologically-enhanced
chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R),
to a biodegradable polyglutamate polymer, which results in a new chemical
entity. When bound to the polymer, the chemotherapy is rendered inactive,
potentially sparing normal tissue's exposure to high levels of unbound,
active chemotherapy and its associated toxicities. Blood vessels in tumor
tissue, unlike blood vessels in normal tissue, are porous to molecules like
polyglutamate. Based on preclinical studies, it appears that XYOTAX is
preferentially distributed to tumors due to their leaky blood vessels and
trapped in the tumor bed allowing significantly more of the dose of
chemotherapy to localize in the tumor than with standard paclitaxel. Once
inside the tumor cell, enzymes metabolize the protein polymer, releasing
the paclitaxel chemotherapy. Preclinical and clinical studies support that
XYOTAX metabolism by lung cancer cells may be influenced by estrogen, which
could lead to enhanced release of paclitaxel and efficacy in women with
lung cancer compared to standard therapies. XYOTAX is being studied in
non-small cell lung and ovarian cancers as well as in several
investigator-sponsored trials for prostate and breast cancers.
















About Cell Therapeutics, Inc.



Headquartered in Seattle, CTI is a biopharmaceutical company committed
to developing an integrated portfolio of oncology products aimed at making
cancer more treatable. For additional information, please visit
cticseattle.



This press release includes forward-looking statements that involve a
number of risks and uncertainties, the outcome of which could materially
and/or adversely affect actual future results. Specifically, the risks and
uncertainties that could affect the development of XYOTAX include risks
associated with preclinical and clinical developments in the
biopharmaceutical industry in general and with XYOTAX in particular
including, without limitation, the potential failure of XYOTAX to prove
safe and effective for treatment of non-small cell lung cancer,
determinations by regulatory, patent and administrative governmental
authorities, competitive factors, technological developments, costs of
developing, producing and selling XYOTAX, and the risk factors listed or
described from time to time in the Company's filings with the Securities
and Exchange Commission including, without limitation, the Company's most
recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by
Italian law, CTI is under no obligation to (and expressly disclaims any
such obligation to) update or alter its forward-looking statements whether
as a result of new information, future events, or otherwise.


Cell Therapeutics, Inc.

cticseattle